IE83273B1 - New protein-polycation-conjugates - Google Patents
New protein-polycation-conjugatesInfo
- Publication number
- IE83273B1 IE83273B1 IE1990/0932A IE93290A IE83273B1 IE 83273 B1 IE83273 B1 IE 83273B1 IE 1990/0932 A IE1990/0932 A IE 1990/0932A IE 93290 A IE93290 A IE 93290A IE 83273 B1 IE83273 B1 IE 83273B1
- Authority
- IE
- Ireland
- Prior art keywords
- transferrin
- nucleic acid
- cells
- dna
- conjugates
- Prior art date
Links
- 210000004027 cells Anatomy 0.000 claims description 128
- 239000012581 transferrin Substances 0.000 claims description 104
- 102000004338 Transferrin Human genes 0.000 claims description 98
- 108090000901 Transferrin Proteins 0.000 claims description 98
- 229920000656 polylysine Polymers 0.000 claims description 64
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 108020004707 nucleic acids Proteins 0.000 claims description 47
- 108010039918 Polylysine Proteins 0.000 claims description 39
- 229920002033 ribozyme Polymers 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 229920000272 Oligonucleotide Polymers 0.000 claims description 12
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 11
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 10
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 229920001949 Transfer RNA Polymers 0.000 claims description 5
- 108020004566 Transfer RNA Proteins 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 230000002068 genetic Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims description 4
- 208000005623 Carcinogenesis Diseases 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 2
- 230000003612 virological Effects 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 87
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 210000004494 Erythroblasts Anatomy 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000002609 media Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 241000287828 Gallus gallus Species 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000005089 Luciferase Substances 0.000 description 13
- 108060001084 Luciferase family Proteins 0.000 description 13
- 229910052742 iron Inorganic materials 0.000 description 13
- 108060006601 PRM1 Proteins 0.000 description 11
- 229940048914 protamine Drugs 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 230000001965 increased Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000001808 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 101700033006 EGF Proteins 0.000 description 7
- 102100010813 EGF Human genes 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 6
- HFACYLZERDEVSX-UHFFFAOYSA-N Benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 6
- 241000271571 Dromaius novaehollandiae Species 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 210000003743 Erythrocytes Anatomy 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 229920001850 Nucleic acid sequence Polymers 0.000 description 5
- 102000002070 Transferrins Human genes 0.000 description 5
- 108010015865 Transferrins Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 4
- 210000000170 Cell Membrane Anatomy 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 230000024881 catalytic activity Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 230000000925 erythroid Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- -1 polylysine Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- 238000004642 transportation engineering Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108010026206 Conalbumin Proteins 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229920002847 antisense RNA Polymers 0.000 description 3
- 108010054176 apotransferrin Proteins 0.000 description 3
- 230000000536 complexating Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 210000001163 Endosomes Anatomy 0.000 description 2
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 235000007959 Psilotum nudum Nutrition 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 230000001744 histochemical Effects 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000004698 iron complex Chemical class 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- HUTBITLDXCEAPZ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound [Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O HUTBITLDXCEAPZ-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- WSMPABBFCFUXFV-UHFFFAOYSA-N 6-amino-2-[[2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid;hydrobromide Chemical compound Br.NCCCCC(C(O)=O)NC(=O)C(N)CC1=CN=CN1 WSMPABBFCFUXFV-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000002960 BFU-E Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- BIWLZRYQMYYVBY-UHFFFAOYSA-N CCC(=S)SC1=NC=CC=C1N1C(=O)CCC1=O Chemical compound CCC(=S)SC1=NC=CC=C1N1C(=O)CCC1=O BIWLZRYQMYYVBY-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 210000004671 Cell-Free System Anatomy 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-SVZMEOIVSA-N D-galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 210000003013 Erythroid Precursor Cells Anatomy 0.000 description 1
- 102100002070 FOS Human genes 0.000 description 1
- 108060001038 FOS Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 102100014519 GPNMB Human genes 0.000 description 1
- 210000002288 Golgi Apparatus Anatomy 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 108010074118 Oncogene Proteins v-erbB Proteins 0.000 description 1
- 108010054076 Oncogene Proteins v-myb Proteins 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 101710012186 SLC7A1 Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 101500002601 human Epidermal growth factor Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N o-Nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 125000003607 serino group Chemical class [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007206 transmembrane glycoprotein Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Description
"New protein—polycation conjugates"
The invention relates to the transporting of
substances with an affinity for polycations,
particularly nucleic acids, into the cell, the
transportation being carried out by means of receptor-
mediated endocytosis.
Antisense RNAs and DNAS have proved to be effective
agents for selectively inhibiting certain genetic
sequences in cell—free systems as well as within the
living cell. Their mode of activity is based on the
specific recognition of a complementary nucleic acid
strand and attachment thereto, thus affecting the
transcription, translation and cleaving processes. This
mechanism of activity theoretically makes it possible to
use antisense oligonucleotides as therapeutic agents
which will block the expression of certain genes (such
as deregulated oncogenes or viral genes) in yiyg. It
has already been shown that short antisense
oligonucleotides can be imported into cells and perform
their inhibiting activity therein (Zamecnik et al.,
1986), even though the intracellular concentration
thereof is low, partly because of their restricted
uptake through the cell membrane owing to the strong
negative charge of the nucleic acids.
Another method of selectively inhibiting genes
consists in the application of ribozymes, i.e. RNA
molecules which recognise specific RNA sequences and are
able to bind to them and cleave them. Here again there
is the need to guarantee the highest possible
concentration of active ribozymes in the cell, for which
transportation into the cell is one of the limiting
factors.
In order to counteract this limiting factor, a
number of solutions have already been proposed.
One of these solutions consists in direct
" 83273
modification of nucleic acids, e.g. by substituting the
charged phosphodiester groups with uncharged methyl
phosphonates (Smith et al., 1986), carbamates (Stirchak
et a1., 1987) or silyl compounds (Cormier et al., 1988)
or using phosphorothioates (Stern et al., 1988).
Another possible method of direct modification consists
in the use of nucleoside analogues (Morvan et a1., 1988,
1988)).
Even though some of these proposals appear to offer
Praseuth et al.,
a promising way of solving the problem, they do have
numerous disadvantages, e.g. reduced binding to the
target molecule and a reduced inhibitory effect. A
chief disadvantage of the in yiyg use of modified
oligonucleotides is the possible toxicity of these
compounds.
An alternative method to the direct modification of
the oligonucleotides consists in leaving the
oligonucleotide itself unchanged and providing it with a
group which will impart the desired properties to it,
e.g. with molecules which will make transportation into
the cell easier. One of the proposed solutions within
the scope of this principle consists in conjugating the
oligonucleotide with polycationic compounds (Lemaitre et
al., 1987).
Various techniques are known for genetic
transformation of mammalian cells ig yitgg, but the use
of these techniques in yiyg is restricted (these include
the introduction of DNA by means of viruses, liposomes,
electroporation, microinjection, cell fusion, DEAE
dextran or the calcium phosphate precipitation method).
Attempts have therefore already been made to
develop a soluble system which can be used in yiyg,
which will convey DNA into the cells in a directed
manner by means of receptor—mediated endocytosis (G.Y.
Wu, C.H. Wu, 1987). This system was developed for
hepatocytes and is based essentially on the following
two facts:
. On the surface of the hepatocytes there are receptors
which bind specific glycoproteins and convey them
into the cell.
. DNA can be bound to polycationic compounds, e.g.
polylysine, by a strong electrostatic interaction,
forming soluble complexes.
The system is based on the principle of coupling
polylysine with a glycoprotein of a kind to which the‘
receptor will respond and then, by adding DNA, forming a
soluble glycoprotein/polylysine/DNA complex which will
be transported to the Cells containing the glycoprotein
receptor and, after the absorption of the complex into
the cell, will make it possible for the DNA sequence to
be expressed.
Stavridis and Psallidopoulos in 1982 proposed the use 5%
transferrin as a carrier molecule for transporting genetic
material, using conjugates obtained by coupling a histone
mixture to transferrin.
Transferrins are a class of related metal-binding
transporting glycoproteins with an in yiyg specificity
for iron. Various mammalian transferrins have been
identified, plasma transferrin supplying the majority of
body tissue with iron. The main producer of transferrin
is the liver.
Transferrin has a molecular weight of about 80,000,
6% of which consists of the sugar residues. A
transferrin molecule is able to bind two molecules of
iron, and this binding requires the presence of
carbonate or bicarbonate ions.
The transferrin receptor, which occurs in a number
of forms which possibly deviate slightly from one
another on the various cells (e.g. in the carbohydrate
group) is a transmembrane glycoprotein with a molecular
weight of about 180,000, whilst a receptor molecule is
able to bind one or possibly two molecules of
transferrin.
At the physiological pH of 7.4, the transferrin
receptor has a very high affinity for Fez transferrin,
lower affinity for the Fe transferrin and virtually no
affinity for apotransferrin, even though the latter
forms a very stable complex with the receptor at a pH of
about 5.
Transferrin receptors have been detected in
particularly large numbers in precursors of
erythrocytes, placenta and liver and in measurable
amounts in a number of other body tissues. A
particularly interesting observation is that the
receptor is highly regulated in growing cells. It has
also been observed that the number of receptors is
substantially increased in neoplastic tissue in yiyg
compared with benign lesions, indicating an increased
iron requirement. The absorption mechanism of the
transferrin-iron complex by receptors and the
intracellular cycle thereof have been thoroughly
researched.
There is still no absolute certainty as to the
exact sequence of events of the release of the iron
molecules by transferrin, although the majority View is
that the molecules are released mainly intracellularly.
In a process which is dependent on energy and
temperature, Fe transferrin or Fez transferrin is bound
to the receptor on the cell membrane. Then the complex
is absorbed into a vesicle, referred to as endosome or
receptosome. This is combined with another vesicle
having a pH of < 5.5; the resulting acidification causes
the iron to be released by the transferrin. The
apotransferrin receptor complex is then transported back
— » «\-\-._...__.....___.. _ ___ _ _ A _ V _ _ I M
to the cell membrane, where the neutral pH causes the
apotransferrin to be released from the receptor into the
surrounding medium. There are indications that the
recycling, the functioning of which is based on the
affinity of the receptor for apo— or iron transferrin,
which varies at acid and neutral pH values, takes place
through vesicles of the Golgi apparatus.
At a molecular level, the initiation of the
transferrin cycle has not yet been explained; there are
merely indications regarding some aspects, e.g. the
possible role of phosphorylation (Huebers et al., 1987).
The aim of the present invention was to prepare new,
15defined transferrin—polycation conjugates.
This aim was achieved with transferrin conjugates in which
histones are replaced by other polycations.
The present invention relates to a conjugate consisting of
transferrin and a polycation covalently bound thereto, which
2Qis characterised in that the polycation is a synthetic
homologous polypeptide or a polyethyleneimine.
It has been found, surprisingly, that nucleic acids
can be efficiently transported into the cell whilst
maintaining their inhibitory activity, using conjugates
according to the invention.
The word "transferrin" as used herein is intended
to encompass both the natural transferrins and also
modified transferrins which are bound by the receptor
and transported into the cell (such modified
transferrins may consist, for example, of a change in
the amino acids or a shortening of the molecule to the
fraction which is responsible for receptor binding).
The molar ratio of transferrin to polycation may,
for example, be 10:1 to 1:4, although it should be borne
in mind that aggregates may be formed. However, this
ratio may if necessary be within wider limits, provided
that it satisfies the condition that complexing of the
nucleic acid or acids takes place and it is ensured that
the complex formed will be bound by the transferrin
receptor and conveyed into the cell; this can easily be
checked by simple experiments carried out from one case
to the next.
The ratio chosen will depend particularly on the
size of the polycation molecule and the number and
distribution of the positively charged groupings, these
criteria being matched to the size and structure of the
nucleic acid or acids to be transported and to any
modifications thereto. The polycations may be identical
or different.
The following compounds may be used as polycations:
a) Synthetic polypeptides such as homologous
polypeptides (polylysine, polyarginine) or
heterologous polypeptides (consisting of two or more
representatives of positively charged amino acids).
b) Polyethyleneimines.
The size of the polycations is preferably selected so
that the sum of the positive charges is about 20 to
500 and this is matched to the nucleic acid which is
to be transported.
The transferrin—polycation conjugates according to
the invention may be produced chemically or, if the
polycation is a polypeptide, by the recombinant method.
Coupling by the chemical method can be carried out in a
manner known per se for the coupling of peptides and if
necessary the individual components may be provided with
linker substances before the coupling reaction (this
procedure is necessary when there is no functional group
suitable for coupling available at the outset, such as a
mercapto or alcohol group). The linker substances are
bifunctional compounds which are first reacted with
functional groups of the individual components, after
which coupling of the modified individual components is
carried out.
Depending on the desired properties of the
conjugates, particularly the desired stability thereof,
coupling may be carried out by means of
a) disulphide bridges, which can be cleaved again under
reductive conditions (e.g. using succinimidyl pyridyl
dithiopropionate (Jung et al., 1981)).
b) Using compounds which are largely stable under
biological conditions (e.g. thioethers, by reacting
maleimido linkers with sulfhydryl groups of the
linker bound to the second component).
c) Using bridges which are unstable under biological
conditions, e.g. ester bonds, or using acetal or
ketal bonds which are unstable under weakly acidic
conditions.
The production of the conjugates according to the
invention by the recombinant method offers the advantage
of producing precisely defined, uniform compounds,
whereas chemical coupling produces conjugate mixtures
which then have to be separated.
The recombinant preparation of the conjugates
according to the invention can be carried out using
methods known for the production of chimeric
polypeptides. The polycationic peptides may vary in
terms of their size and amino acid sequence. Production
by genetic engineering also has the advantage of
allowing the transferrin part of the conjugate to be
modified, by increasing the ability to bind to the
receptor, by suitable mutations, for example, or by
shortening the transferrin fraction to the part of the
molecule which is responsible for the binding to the
receptor. It is particularly expedient for the
recombinant preparation of the conjugates according to
the invention to use a vector which contains the
sequence coding for the transferrin part as well as a
polylinker into which the required sequence coding for
the polycationic peptide is inserted. In this way, a
set of expression plasmids can be obtained, of which the
plasmid containing the desired sequence can be used as
necessary in order to express the conjugate according to
the invention.
The nucleic acids which are to be transported into
the cell may be DNAs or RNAS, with no restrictions as to
the nucleotide sequence. The nucleic acids may be
modified, provided that this modification does not
affect the polyanionic nature of the nucleic acids;
these modifications include, for example, the
substitution of the phosphodiester group by
phosphorothioates or the use of nucleoside analogues.
Nucleic acids which may be used within the scope of
the present invention include particularly those which
are to be transported into the cell for the purpose of
inhibiting specific gene sequences. These include
antisense oligonucleotides and ribozymes, optionally
together with a carrier nucleic acid. with regard to
the size of the nucleic acids the invention again
permits a wide range of uses. There is no lower limit
brought about by the transporting system according to
the invention; any lower limit which might arise would
be for reasons specific to the application, e.g. because
antisense oligonucleotides with less than about 10
nucleotides would hardly be suitable owing to their lack
of specificity. Using the conjugates according to the
invention it is also possible to convey plasmids into
the cell, the smaller plasmids which are used as carrier
nucleic acids (e.g. retroviral vectors with up to
5000 bp) being of particular practical use. It is also
possible to convey different nucleic acids into the cell
at the same time using the conjugates according to the
invention.
A further advantage of the present invention is the
fact that there are polymorphisms for transferrin and
the receptor which can be exploited for the deliberate
transporting of inhibiting nucleic acids into specific
cells.
Within the scope of the present invention it has
been possible to demonstrate that transferrin—polycation
conjugates can be efficiently absorbed into living cells
and internalised. The conjugates or complexes according
This
means that they can be administered repeatedly and thus
to the invention are not harmful to cell growth.
ensures a constantly high expression of genes inserted
into the cell.
It has also been possible to show that the
polycation—transferrin conjugates can functionally
The fact
that the transferrin~polycation/DNA complexes are
replace the native transferrin—iron complex.
absorbed through the cell by means of the transferrin
receptor has been confirmed using the luciferase gene as
DNA component. It has been shown that native
transferrin efficiently displaces the transferrin-
polycation/DNA complex, and this has been measured by
the reduction in the luciferase activity in the cell.
The experiments carried out within the scope of
this invention have also demonstrated that a tRNA
ribozyme gene (the ribozyme being directed against a
V-erbB sequence) can be introduced into erbB—transformed
chicken cells using a conjugate according to the
invention (polylysine~transferrin) and can attenuate the
transforming activity of the oncogene. This result is
all the more significant as only a small amount of
ribosome gene was used in these experiments.
The ratio of nucleic acid to conjugate can vary
within a wide range, and it is not absolutely necessary
to neutralise all the charges of the nucleic acid. This
ratio will have to be adjusted for each individual case
depending on criteria such as the size and structure of
the nucleic acid which is to be transported, the size of
the polycation and the number and distribution of its
charges, so as to achieve a ratio of transportability
and biological activity of the nucleic acid which is
favourable to the particular application. This ratio
can first of all be adjusted coarsely, for example by
using the delay in the speed of migration of the DNA in
a gel (e.g. using the mobility shift on an agarose gel)
or by density gradient centrifugation. Once this
provisional ratio has been obtained, it may be expedient
to carry out transporting tests with the radioactively
labelled complex with respect to the maximum available
activity of the nucleic acid in the cell and then reduce
the proportion of conjugate if necessary so that the
remaining negative charges of the nucleic acid are not
an obstacle to transportation into the cell.
The preparation of the transferrin-
polycation/nucleic acid complexes, which are also a
subject of the invention, can be carried out using
methods known per se for the complexing of polyionic
compounds. One possible way of avoiding uncontrolled
is to mix the two
all at a high (about 1
molar) concentration of common salt and subsequently to
aggregation or precipitation
components together first of
adjust to physiological saline concentration by dialysis
or dilution. Preferably, the concentrations of DNA and
conjugate used in the complex forming reaction are not
too high (more than 100 pg/ml), to ensure that the
complexes are not precipitated.
The preferred nucleic acid component of the
transferrin—polycation-nucleic acid complex according to
the invention is antisense—DNA, antisense-RNA or a
ribozyme or the gene coding for it. When ribozymes and
antisense—RNAs are used it is particularly advantageous
to use the genes coding for these RNAs which inhibit the
function of RNA, preferably together with a carrier
gene. By introducing the gene into the cell, a
substantial amplification of the RNA is ensured, as
against the importing of RNA as such, and consequently a
sufficient amount to inhibit the biological reaction is
ensured. Particularly suitable carrier genes are the
transcription units, e.g. tRNA genes, required for
transcription by polymerase III. Ribozyme genes, for
example, may be inserted into them in such a way that
when the transcription is carried out the ribozyme is
part of a compact polymerase III transcript. Using the
transporting system according to the present invention
it is possible to intensify the activity of these
genetic units, by guaranteeing an increased initial
concentration of the gene in the cell.
The invention further relates to a process for
introducing nucleic acid or acids into human or animal
cells, preferably forming a complex which is soluble
under physiological conditions.
The invention further relates to pharmaceutical
preparations containing as the active component a
nucleic acid which specifically inhibits a gene,
complexed with a transferrin—polycation conjugate, e.g.
in the form of a lyophilisate. Such pharmaceutical
preparations may be used to inhibit pathogenic viruses
such as HIV or related retroviruses, oncogenes or other
key genes which control growth and/or differentiation of
cells, e.g. the c-fos gene or the c—myc gene, together
with antisense oligonucleotides, antisense
oligonucleotide analogues or ribozymes or the DNAs
coding for them, optionally together with a carrier
nucleic acid, in humans or animals.
Another field of use is in fighting diseases by
inhibiting the production of undesirable gene products,
e.g. the major plaque protein which occurs in
Alzheimer's disease or proteins which cause autoimmune
diseases.
The invention will now be illustrated by way of the
following non—limiting Examples with reference to the
drawings in which:—
Figure 1 is a graph of absorption at 280 nm of
material eluted from an ion exchange column (Example
1c):
Figures 2 to 4 are photographs of stained
electrophoretic gels (Examples 1c, 3c and 4);
Figure 5 comprises photomicrographs of cells under
fluorescent light (Example 5);
Figures 6A and B are graphs showing haemoglobin
levels against days in culture and concentration of an
iron—bearing substance respectively (Example 7);
Figure 7 shows nucleic acid sequences insertable
into a plasmid;
Figures 8 and 9 are graphs showing light emitted
from cells versus pg DNA;
Figures 10A and 10B are graphs showing light
emitted from cells with respect to the presence of
certain polycations/polycation—conjugate;
Figure 11 illustrates three mRNA sequences;
Figure 12 is a photograph of an electrophoretic
gel;
Figure 13 is a graph showing the relationship of
bound substance to total substance as described in
Example 11;
Figures 14 and 15 are graphs of cell fluorescence
as described in Examples 12 and 13.
Example 1
Preparation of transferrin-polylysine 90 conjugates
Coupling was carried out using methods known from
the literature (Jung et al., (1981)) by introducing
disulphide bridges after modification with succinimidyl—
pyridyl dithiopropionate.
a) 3~(2—Pyridyldithio)propionate~modified transferrin:
ml of a solution, gel-filtered over Sephadex
G—25, of 120 mg (1.5 umol) of transferrin (from chicken
albumin, Sigma, Conalbumin Type I, iron—free) in 3 ml of
0.1 M sodium phosphate buffer (pH 7.8) were mixed with
200 pl of 15 mM ethanolic solution of succinimidyl 3-(2-
pyridyldithio)propionate (3 uM, SPDP, Pharmacia) with
vigorous shaking and the mixture was left to react for 1
hour at ambient temperature with occasional shaking.
Low molecular reaction products and traces of reagent
were removed using a gel column (Sephadex G—25,
X 180 mm, 0.1 M sodium phosphate buffer pH 7.8) and
ml of the product fraction were obtained; the content
of pyridyl dithiopropionate residues bound to
transferrin was determined by means of one aliquot,
after reduction with dithiothreitol, by photometric
measurement of the quantity of pyridin~2—thione released
and the result was 2.6 umol. Human transferrin (Sigma,
iron—free) was modified in exactly the same way.
b) Mercaptopropionate—modified polylysine 90 (pL 90):
A solution of 18 mg (about 1.0 umol) of
poly(L)lysine—hydrobromide (Sigma, fluoresceinisothio—
cyanate (= FITC)—labelled, molecular weight of about
18,000 — Corresponding to an average degree of
polymerisation of about 90) in 3 ml of 0.1 M sodium
phosphate (pH 7.8) was filtered over Sephadex G—25 (the
fluorescent labelling was carried out in sodium
bicarbonate buffer pH 9 for 3 hours). The polylysine
solution was diluted with water to 7 ml, combined with
270 pl of a 15 mM ethanolic solution of SPDP with
thorough shaking and then left to react for 1 hour in
the dark at ambient temperature and with occasional
shaking. After the addition of 0.5 ml of 1 M sodium
acetate buffer (pH 5.0) the mixture was filtered over
Sephadex G-25 to separate off any lower molecular
substances (eluant: 20 mM sodium acetate buffer pH 5.0).
The product fraction (ninhydrin staining, fluorescence)
was evaporated down in yggug, adjusted to pH about 7
with buffer, a solution of 23 mg (150 umol) of
dithiothreitol in 200 ul of water was added and the
mixture was left to stand for 1 hour in the dark under
argon at ambient temperature. Excess reducing agent was
separated off by further gel filtration (Sephadex G~25,
14 X 130 mm column, 10 mm sodium acetate buffer pH 5.0)
and 3.5 ml of product solution of fluorescently labelled
polylysine were obtained, containing 3.8 pmol of
mercapto groups (photometric determination using
Ellman's reagent, 5,5'—dithiobis(2~nitrobenzoic acid).
c) Transferrin—polylysine conjugates:
The solution of modified transferrin obtained in a)
(7 ml in 0.1 M sodium phosphate buffer pH 7.8, about
1.5 umol transferrin with about 2.6 umol pyridyl
dithiopropionate residues) was rinsed with argon; 2.0 ml
of the solution of mercapto—modified polylysine obtained
in b) (in 10 mm sodium acetate buffer pH 5.0,
corresponding to about 0.6 umol of polylysine with about
2.2 umol of mercapto groups) were added, the mixture was
rinsed with argon, shaken and left to react for 18 hours
at ambient temperature in the dark and under argon. The
reaction mixture was diluted with water to 14 ml and
separated by ion exchange chromatography (Pharmacia Mono
S column HR 10/10, gradient elution, buffer A: 50 mM
HEPES pH 7.9, buffer B: A + 3 M sodium chloride,
0.5 ml/min, Fig. 1).
eluted at the start, product fractions at about
Non~conjugated transferrin was
.66 — 1.5 M sodium chloride.
Averaged over all the fractions, conjugates were
obtained containing a ratio of transferrin to polylysine
of l.3:1.
The conjugated products (ninhydrin staining, in UV
at 280 nm protein absorption, and fluorescence
measurement of FITC-labelled polylysine at 495 nm) were
collected in 6 fractions each containing about 10 mg of
transferrin. The fractions were first dialysed against
a 100 mm iron(III)citrate solution (adjusted to pH 7.8
with sodium hydrogen carbonate) and then twice more with
1 mM HEPES buffer (pH 7.5).
Sodium dodecylsulphate gel electrophoresis (10%
SDS, 8% polyacrylamide), see Fig. 2, showed an
approximately equal content of transferrin in all 6
fractions after pretreatment with 2-mercaptoethanol
(Fig. 2A), whereas in the unreduced samples there were
no visible bands for free transferrin, only less widely
migrating conjugates (Fig. 2B, T = untreated
1-6 =
transferrin; conjugate fractions 1-6).
Example 2
Preparation of transferrin-polylysine 270 and
transferrin—polylysine 450 coniuqates (pL27O and pL450)
a) Modified transferrin was produced analogously to
Example 1 a)
b) Preparation of modified polylysine 270 and
polylysine 450
A gel—filtered solution of 0.33 umol polylysine 270
(with an average degree of polymerisation of 270 lysine
groups, with or without fluorescent labelling;
corresponding to 19 mg of hydrobromide salt) in 1.2 ml
of 75 mM sodium acetate buffer was adjusted to pH 8.5 by
the addition of sodium carbonate buffer. 182 pl of a
mM ethanolic solution of SPDP (1.9 umol) was added
200 pl 1 M
with vigorous stirring. One hour later,
sodium acetate pH 5 were added; after gel filtration
with 20 mM sodium acetate, a solution was obtained
containing 0.27 umol of polylysine 270 with 1.3 pmol
mercapto groups (4.8 linkers per polylysine chain).
Analogously, 0.20 umol of polylysine 450 (with an
average degree of polymerisation of 450 lysine groups)
were modified with 2.25 umol of SPDP, obtaining a
product of 0.19 nmol polylysine 450 with 2.1 nmol
mercapto groups (11 linkers per polylysine chain).
Analogously to Example 1 b), the dithiopyridine groups
were reduced with dithiothreitol, in order to obtain the
free sulfhydryl components.
c) Preparation of transferrin—polylysine conjugates
Transferrin—polylysine 270 conjugates were prepared
by mixing 1.0 nmol of modified transferrin in 100 mM
phosphate buffer, pH 7.8, with 0.14 nmol of modified
polylysine 270 (in 20 mM sodium acetate buffer) with the
exclusion of oxygen in an argon atmosphere. After 18
hours at ambient temperature the reaction mixture was
diluted with water to a volume of 10 ml and fractionated
by cation exchange chromatography (Pharmacia Mono S
column HR 10/10; gradient elution, buffer A: 50 mM HEPES
pH 7.9; buffer B: A + 3 M sodium chloride; UV absorption
at 280 nm and fluorescence measurement, excitation
480 nm, emission 530 nm). The excess of non~coupled
transferrin was eluted first; the product fractions were
eluted at between 30% and 50% gradient B and pooled in 3
conjugate fractions (molar ratios of transferrin to
polylysine: pool A: 5.5 to 1; pool B: 3.4 to 1; pool C:
1.8 to 1). The conjugates were obtained in an average
yield of 0.23 umol transferrin with 0.075 pmol of
polylysine 270.
Transferrin-polylysine 450 conjugates were prepared
in a similar manner, starting from 1.2 nmol of modified
transferrin according to Example 1 a) (in 20 mM HEPES pH
.9 containing 80 mM sodium chloride) and 71 nmol of
mercapto—modified polylysine 450 according to Example
2 b) in acetate buffer.
The reaction mixture was purified by gel permeation
chromatography (Pharmacia Superose 12 column, 1 M
guanidine chloride pH 7.3) and after dialysis (20 mM
HEPES pH 7.3, containing 100 mM sodium chloride) yielded
transferrin—polylysine-conjugates containing 0.40 umol
of transferrin with 38 nmol of polylysine 450.
Iron was incorporated by adding 6 — 12 ul of 100 mM
iron citrate buffer (containing sodium bicarbonate
adjusted to pH 7.8) to the samples, per mg of
transferrin fraction.
Example 3
a) Preparation of transferrin~protamine conjugates
Modified transferrin was prepared as in Example
1 a).
Preparation of 3—mercaptopropionate—modified
protamine
To a solution of 20 mg (3 umol) of protamine
trifluoracetate salt (prepared by ion exchange
chromatography from salmon protamine (2 salmin)—
sulphate, Sigma) in 2 ml of DMSO and 0.4 ml of
isopropanol, containing 2.6 pl (15 pmol) of ethyl
diisopropylamine, was added a solution of 30 pmol of
SPDP in 250 pl of isopropanol and 250 pl of DMSO in
After 3.5
hours at ambient temperature the solution was evaporated
several batches over a period of one hour.
down under high vacuum and taken up in 0.5% acetic acid
containing 10% methanol. Gel filtration (Sephadex G10;
0.5% acetic acid with 10% methanol) yielded, after
lyophilisation, 16 mg (2.5 umol of protamine acetate
salt, modified with 2.5 umol of dithiopyridine linker.
Reduction of 1.75 umol of protamine (containing
.75 umol of linker) with 16 mg of dithiothreitol in
sodium bicarbonate buffer, pH 7.5, for 1 hour under
argon, followed by adjustment of the pH to 5.2 and gel
filtration over Sephadex G10 with 20 mM sodium acetate
buffer, pH 5.2, yielded a protamine solution modified
with 1.6 umol of mercaptopropionate linker.
c) Preparation of transferrin—protamine conjugates
The reaction of the protamine solution obtained in
b) (1.6 umol linker) with 1.34 umol of transferrin
(modified with 3.1 umol of dithiopyridine linker) and
subsequent purification by cation exchange
chromatography as described for transferrin—polylysine
conjugates, yielded four product fractions A — D eluted
one after the other, containing 90, 320, 240 and
nMol, respectively, of modified transferrin with
increasing amounts of protamine (determined by SDS gel
electrophoresis; 10% SDS, 8% polyacrylamide, Coomassie
blue staining). Fig. 3 shows the results of the SDS gel
electrophoresis. The Tfprot conjugate fractions A — D
more slowly migrating bands (a), whereas in fi-
mercaptoethanol—reduced samples (b) only the transferrin
band was visible. Dialysis and the incorporation of
iron were carried out as described for the transferrin-
polylysine conjugates TfpL270 and TfpL45O in Example 2.
Example 4
Preparation of complexes of transferrin—polycation
conjugates with DNA
The complexes were prepared by mixing dilute
solutions of DNA (30 pg/ml or less) with the
transferrin—polycation conjugates. In order to prevent
precipitation of the DNA complexes, phosphate—free
buffer was used (phosphates reduce the solubility of the
conjugates). The binding of the DNA to the polycation
conjugates under physiological ionic conditions was
confirmed by a gel mobility shift assay using lambda DNA
”P—labelled at the 3'—end, cut with EcoR 1/Hind III
(Fig. 4). To each sample of 1 pl (35 ng) of DNA were
added 3 uml of a 100 mM HEPES buffer pH 7.9, containing
1 M sodium chloride, and the samples were mixed with
increasing amounts (10 ng to 1000 ng) of transferrin
conjugates in 11 pl of aqueous solution, resulting in a
final concentration of sodium chloride of 200 mM.
Electrophoresis on a 1% agarose gel with 1 X TAE eluting
buffer was carried out at 50 Volts (45 mA) for 2.5
hours; the gel was dried, followed by autoradiography
for 2 hours at —80°C using an XAR film (Kodak).
Example 5
Transporting of transferrin—polylysine conjugates into
living cells
In order to demonstrate that the transferrin-
polylysine conjugates described in Example 1 are
efficiently absorbed into living erythroblasts, FITC-
labelled conjugates were used. It is known (Schmidt et
al, 1986) that FITC-labelled transferrin was detectable
in vesicles inside the cell (when examined under a
fluorescence microscope) after some hours‘ incubation
with erythroblasts from which transferrin had previously
been removed.
conjugates (or, as a control, the corresponding amount
conjugates (or, as a control, the corresponding amount
of sterile twice distilled water), the cells were
incubated at 37°C in the presence of 10 ng/ml EGF in
order to maintain the transformed state). After 24 and
48 hours, about 5x105 cells were removed, washed once in
phosphate—buffered physiological saline (PBS; pH 7.2),
fixed with 50 times the volume of a mixture of 3.7%
formaldehyde and 0.02% glutaraldehyde in PBS (10
minutes, 40°C), washed once in PBS, embedded in Elvanol
and examined under a fluorescence microscope (Zeiss
Axiophot, Narrow Band FITC and TRITC activation). At
the same time, the growth rate of the cells was
determined in other aliquots of the various mixtures.
100 pl cell suspension were taken and the incorporation
of 3H-thymidine (8 pci/ml, 2 hours) was determined as
described in Leutz et al, 1984. Fig. 5 shows that the
erythroblasts incubated with transferrin—polylysine show
2 to 10 strongly fluorescing vesicles after 24 hours,
which cannot be detected in the controls. Table A shows
that, with the exception of fraction 6, all the
conjugates have been absorbed by virtually all the
cells.
Fig. 5 shows fluorescence images of chicken
erythroblasts which have been incubated for 24 hours
without (A) or with FITC—labelled transferrin-polylysine
conjugates (B,C). when they are activated with blue
light (B, in order to detect FITC), significantly more
fluorescing vesicles can be detected in each cell. The
specificity of this fluorescence is shown by the fact
that the vesicle fluorescence does not occur when
activated with green light (C: at which a similar non—
specific fluorescence of the cells can be seen as in A)
(C) -
The fact that the cells grow equally rapidly in all
the samples (as measured by the incorporation of
tritiated thymidine (3H TdR), cf Table A at the end of
the description) shows that the cells are not
dimensioned by the polylysine constructs and
consequently non—specific uptake (e.g. through cell
membranes which have become permeable) can be ruled out.
Example 6
The objective of the tests carried out in this
Example was to show that the transferrin—polylysine
conjugates used here are used by the cell in the same
way as native transferrin, i.e. they pass through the
normal transferrin cycle with similar efficiency.
Erythroblasts which can be induced to mature into normal
erythrocytes by "switching off" the transforming
oncogene are particularly suitable as a test system for
this purpose (Beug et al, 1982). The literature shows
that for normal maturation such cells require high
concentrations of transferrin~iron complex (100 to
200 ug/ml, 3 times lower concentrations prevent the
cells from maturing and will result in the death of the
cells after several days (Kowenz et al, 1986)). It has
also been shown (Schmidt et al 1986) that recycling,
i.e. the reuse of transferrin receptors and hence a
transferrin cycle proceeding at optimum speed are
indispensible for normal in yitrg differentiation.
Erythroblasts (transformed by the EGF~receptor
retrovirus) were induced to differentiate by the removal
of EGF and the addition of an optimum amount of
partially purified chicken erythropoietin (Kowenz et
al., 1986, free from transferrin). Incubation was
carried out at a cell concentration of lxlofimfl in
transferrin—free differentiating medium at 42“C and 5%
CO2. At the start of incubation, either native
transferrin—iron complex (Sigma, 100 pg/ml) was added or
the iron—saturated transferrin-polylysine conjugates
were added (concentration again 100 pg/ml). The growth
and maturity of the cells were analysed are 24 and 48
hours by the following methods:
. by determining the number of cells (using a Coulter
Counter, Model ZM, Beug et al, 1984)
. by recording cell size distributions (using a Coulter
Channelyzer Model 256) and
. by photometric determination of the haemoglobin
content of the cells (Kowenz et al., 1986).
In addition, aliquots of the mixtures were
centrifuged after 72 hours in a cytocentrifuge (Shandon)
on an object carrier and subjected to histochemical
investigation to detect haemoglobin (staining with
neutral benzidine plus Diff—Quik rapid staining for
blood cells, Beug et al 1982).
The results in Table B at the end of the
description clearly show that cells which were induced
to differentiate in the presence of the polylysine-
transferrin conjugates fractions 1 to 5 mature just as
efficiently and as fast as those which were incubated
with native transferrin—iron. The cells in the
transferrin—free controls, on the other hand, showed a
much slower cell growth and accumulated only small
amounts of haemoglobin. Investigation of cell phenotype
on stained cytospin preparations showed that the cells
incubated with polylysine-transferrin conjugates were
matured into late reticulocytes (late reticulocytes,
Beug et al., 1982) in just the same way as those which
had been treated with native transferrin, whereas the
cells incubated without transferrin constituted a
mixture of disintegrated and immature cells resembling
erythroblasts (Schmidt et al, 1986). only the cells
treated with transferrin-polylysine fraction 6 showed a
lower haemoglobin content and a higher percentage of
immature cells (Table B). This shows that fraction 6
conjugated with a particularly large amount of
polylysine operates less well in the transferrin cycle.
At the same time, this result indicates the sensitivity
of the test method.
Example 7
Just as in Example 6, various transferrin-
polylysine conjugates and transferrin—protamine
conjugates were examined for their ability to
functionally replace the native transferrin-iron complex
in the maturation of chicken erythroblasts into
erythrocytes.
It has already been shown that terminally
differentiating chicken erythroblasts demand an
optimally functioning transferrin cycle; i.e. without
transferrin or if the transferrin receptor recycling is
inhibited, the cells die off
Schmidt et al., 1986).
(Kowenz et al., 1986;
Since the partially purified
chicken erythropoietin normally used still contains
transferrin, EPO was replaced by a transferrin—free,
partially purified erythroid growth factor in order to
permit erythroid differentiation (REV factor; Kowenz et
al., 1986; Beug et al., 1982): as target cells,
erythroblasts which had been transformed with a
retrovirus containing the human epidermal growth factor
receptor (EGFR) together with a temperature—sensitive
v—myb oncogen were replicated in CFU-E medium (Radke et
al., 1982) in the presence of 20 ng/ml of EGF. These
cells are activated to replicate abnormally by EGF,
whilst the withdrawal of the growth factor EGF and the
simultaneous addition of REV factor causes the cells to
enter into normal differentiation. After being washed
twice in transferrin-free medium the cells were
transferred into transferrin—free medium and varying
quantities of iron-saturated transferrin or transferrin-
polycation conjugates were added (before
After 1, 2
or after being
complexed with plasmid DNA). and 3 days‘
incubation at 42°C the differentiating state of the
cells was determined by cytocentrifugation and
histochemical staining or by quantitative haemoglobin
measurement.
The results of these tests are shown in Fig. 6 or
Table C (which is at the end of the description).
The cells (1 x 157ml) were added to conalbumin—free
differentiating medium (Zenke et al., 1988),
supplemented by 1 pg/ml of insulin and REV factor at an
optimum concentration (Kowenz et al., 1986; dilution
l:5,000), once without additives (triangles), once with
and once with iron-
(100 pg/ml in
After incubation for 24
iron—saturated conalbumin (circles)
saturated TfpL 270 conjugates (squares)
each case); in 14 mm dishes.
and 48 hours, the haemoglobin content was
photometrically determined in 100 pl aliquots. The
shaded area shows the haemoglobin content of cells grown
without transferrin (average from 4 measurements;
Fig. 6A).
In order to analysis the erythroid differentiation
as a function of the concentration of transferrin or
transferrin—polylysine, the cells were placed in medium
containing the specified amounts of iron—saturated
conalbumin (open circles), TfpL 90 (open squares) or
TfpL 270 (solid squares) as described above and after 2
days the haemoglobin content was determined
photometrically (Fig. 6B).
Table C:
The erythroid differentiation was monitored by
photometric haemoglobin measurement (see Fig. 6), by
counting in a Coulter counter or by cytocentrifugation
and subsequent neutral benzidine staining (to determine
the haemoglobin) plus histological dyes (Diff Quik; Beug
et al., 1982b).
and transferrin conjugates in test 1 were 60 ug/ml; in
The DNA
The final concentrations of transferrin
tests 2 and 3 they were 100 pg/ml.
concentration in test 2 was 10 pg/ml. The proportion of
disintegrated cells, mature cells (LR: late
reticulocytes; E: erythrocytes) and immature cells (Ebl)
was determined using the methods described by Beug et
al., 1982b and Schmidt et al., 1986.
obtained show that two different transferrin—polylysine
The results
conjugates (TfpL90 or TfpL270) as well as the
transferrin—protamine conjugate are capable of
functionally replacing native transferrin, by ensuring
the rapid transfer of iron into differentiating red
cells, the specific activity thereof being 1.5 to 2
times lower (cf. Fig. 6). The complexing of DNA with
transferrin—polylysine 270 and transferrin protein did
not materially alter the biological activity of the
conjugates. In a control experiment it was established
that, when polylysine or protamine is added, mixed with
a suitable quantity of iron citrate instead of the
transferrin conjugates, the cells were enable to
differentiate and died off, just like the cells in the
comparison samples which had been incubated without
transferrin.
All in all, the tests according to Examples 6 and 7
have shown that both types of polycation—transferrin
conjugates transported iron only slightly less
efficiently than natural transferrin.
Example 8
Polylysine-transferrin conjugates make it possible
for DNA to be absorbed into chicken erythroblasts.
The present Example was intended to investigate
whether DNA of a size corresponding to that of tDNA
ribozymes (see Fig. 7) is capable of being efficiently
transported into the interior of the cell by
transferrin-polylysine conjugates. In the present
Example, tDNA with an insert of the sequence
CGTTAACAAGCTAACGTTGAGGGGCATGATATCGGGCC
CCGGGCAATTGTTCGATTGCAACTCCCCGTACTATAGC
molecular weight about 300,000 was used, terminally
labelled with gamma 32P ATP (Maniatis). About 0.3 pg of
this DNA, dissolved in 20 pl of TE buffer were mixed
either with 10 pg of native transferrin, with 10 ug of
transferrin—polylysine conjugate fraction 3, in each
case dissolved in 50 pl of twice distilled water plus
400 pg/ml of bovine serum albumin (Beug H., et al.,
) or with 50 pl of this solvent without transferrin.
The DNA protein mixtures were each added to 2 ml of
transferrin~free differentiating medium, 4x106 chicken
erythroblasts were added (which had previously been
transformed with an EGF receptor retrovirus and pre—
incubated for 18 hours in transferrin—free medium in the
presence of EGF (Khazaie K., et al., 1988) and the
mixtures were incubated for 8 hours at 37°C and 5% COT
Then the cells were centrifuged off, the supernatant was
removed and the cells were washed 3 times in
transferrin—free medium. Cell sediment and culture
medium were taken up in 1% SDS, 1 mg/ml of proteinase K,
300 mM NaCl, 20 mM tris pH 8.0, 10 mM EDTA (PK/SDS
buffer), incubated for 30 minutes at 37°C, extracted
with phenol/chloroform, and the DNA isolated by ethanol
precipitation. Isolated DNA with a radioactivity of
2000 cpm in all were separated on a non—denaturing 3.5%
acrylamide gel (TBE, Maniatis) and the DNA was detected
in the cell
sample treated with transferrin—polylysine,
by autoradiography. It was shown that,
approximately 5 to 10 times more DNA had been absorbed
by the cells than in the control samples with native
transferrin.
1~;>semp,le_2
Polylysine—transferrin conjugates make it possible for
p1asmid—DNA to be absorbed into and expressed in chicken
erythroblasts.
In these tests, plasmid—DNA containing the Photinus
pyralis luciferase gene as reporter gene was used to
For this
purpose, pRSVluc plasmid DNA (De Wet, J.R., et al.,
investigate gene transfer and expression.
) was prepared using the Triton-X lysis standard
method (Maniatis), followed by CsCl/EtBr equilibrium
density gradient centrifugation, decolorising with
butanol—1 and dialysis with 10 mm Tris/HCl, pH 7.5, 1 mm
EDTA. In a typical complex forming reaction, 10 pg of
transferrin—polylysine or transferrin—protamine
conjugates were slowly added, with careful stirring, to
3 pg of pRSVluc plasmid DNA contained in 250 pl of 0.3 M
NaCl (it was established that these conditions are
adhered to, up to 100 pg of transferrin—po1ycation
conjugate and 30 pg of plasmid—DNA can be used in a
final volume of 500 pl without precipitation of the
conjugate/DNA complexes). After 30 minutes at ambient
temperature, the complexes were added directly to
— 10 x 106 HD3 Cells (0.5 — 1 x 105 cells per ml, EBM+H
1982a; 37°C, and the
(the cell
line used was the ts~v-erbB transformed chicken
erythroblast cell line HD3).
medium (Beug et al., 5% Cop
mixtures were incubated for 16 to 48 hours
The cells were harvested
(5 min at 1500 X g, 4°C, washed twice with phosphate-
buffered saline (PBS) and taken up in 100 pl of 0.25 M
tris/HCl, pH 7.5. Cell extracts were prepared by three
cycles of freezing and thawing, followed by high—speed
centrifugation (15 min, 18,500 X g, 4°C). Aliquots of
these cell extracts were examined for the presence of
luciferase enzyme activity (De Wet, J.R., et al., 1987).
The bioluminescence was measured using clinilumate
(Berthold, Wildbach, BRD). It was established that the
presence of the transferrin—po1ycation/DNA complexes in
the culture medium does not have any harmful effects on
cell growth or replication. As can be seen from Fig. 8,
maximum luciferase activity was achieved when using 3 pg
of DNA/10 pg of TfpL and 0.3 - 1 pg of DNA/Tfprot.
Assuming that all the conjugate/DNA complexes formed
were identical, this corresponds to a molar ratio of 25
or 75 conjugate molecules per molecule of plasmid DNA.
It can be concluded from this that the DNA in the
complex is entirely covered by the conjugate molecules,
and indeed at a conjugate/DNA ratio which obviously
guarantees electroneutrality (calculated on the basis of
the positive charges in the polycation which are
necessary in order to neutralise the negative charges of
the phosphate groups in the DNA). This assumption
agrees with the observation that, compared with
transferrin—polylysine, three times more
transferrin/protamine, less strongly positively charged,
is required for optimum complex forming and gene
transfer. This assumption also accords with the results
for the conjugate/DNA ratio obtained in Example 4
required for efficient complex formation.
The sensitivity of this gene transfer system was
determined using a TfpL/DNA ratio which had been
adjusted to the optimum for complex forming. The
results of these tests are shown in Fig. 9: less than
1 ng of plasmid DNA coding for luciferase still shows a
detectable signal. The use of more than 2 pg of plasmid
DNA, complexed with 6 pg of TfpL or 20 pg of Tfprot,
does not result in any further increase in luciferase
activity, presumably because the system is saturated.
It was also found that no special concentration of salt
or ions is needed for the complex forming, since
TfpL/DNA complexes formed at various salt concentrations
(0, 20, 50 100, 200 mM NaCl) prove to be equally
effective in gene transfer experiments. (Fig. 8 and
Fig. 9: circles indicate Tfprot, squares indicate TfpL).
It was possible to demonstrate that the absorption of
transferrin—polycation/DNA complexes into the cells was
effected via the transferrin receptor.
illustrated in Fig. 10A,
First of all, as
it was found that the
luciferase activity achieved by TfpL—DNA complexes is at
least 100 times higher than the activity measured for
pL—DNA complexes. A comparison test shows that a
mixture of polylysine and transferrin alone did not
facilitate the uptake of plasmid DNA. In another test,
an excess of native transferrin was added to a constant
quantity of TfpL—DNA complex. Fig. 10B shows that free
transferrin in the medium efficiently competes for the
DNA uptake mediated by TfpL, resulting in a reduction in
the luciferase enzyme activity. From this it can be
concluded that the uptake of the TfpL-DNA complexes by
the cell is effected via the transferrin receptor.
Example 10
In preliminary tests it was established, by the
transfection of chicken fibroblasts with erbB cut DNA
that the erbB cut ribozyme~tDNA is expressed in chicken
cells.
This Example shows that tDNA ribozymes directed
against the erbB oncogene can be introduced into erbB-
transformed chicken erythroblasts with the aid of
polylysine-transferrin conjugates and can weaken the
transforming activity of the oncogene.
Two tRNA ribozyme genes, directed against the
translation initiation region of erbB, were constructed
(see Figs. 7 and 11). About 100 pg of each plasmid
containing the gene were digested in EcoRI in order to
free the tRNA ribozyme gene on a 325 bp fragment.
The digestion products were terminally labelled by
means of klenow fragment and purified by gel
electrophoresis using a 2% agarose/TBE gel. The vector
fragment and the tRNA—ribozyme gene fragments were
located by staining with ethidium bromide, cut out and
recovered by electroelution, extraction with
phenol/chloroform and chloroform and ethanol
precipitation. The purified, radioactively labelled DNA
fragments were then used, with the aid of the
transferrin-polylysine transporting system, to determine
the uptake and inhibition of the erbB—RNA. The vector
pSPT 18 was used as the control DNA.
The test cell system used was a chicken
erythroblast cell line transformed by a temperature-
sensitive mutant (ts 34, Graf et al. 1978) of the avine
erythroblastosis virus AEV (Beug et al, 1982 b). The
erbA oncogene which is also expressed in these cells can
be inhibited by a specific protein kinase inhibitor
(H 7). (It was found that the V—erbA oncogene is
phosphorylated in yiyg and in yitrg (i.e. as a
bacterially expressed protein) at two sites, namely
Ser 28 and Ser29, by protein kinase C or by cAMP—
dependent protein kinase. Mutation of these serines to
form alanines prevents phosphorylation and destroys the
v—erbA oncogene activity. H7 is a specific inhibitor of
these two kinases and is capable of selectively stopping
the changes caused by v—erbA (e.g. blocking of
differentiation) in erythroblasts which contain v—erbA—
v—erbB.)
It is known that erythroblasts in which the erbB
oncogene is inactivated — e.g. by increasing the
temperature in the case of a temperature-sensitive erbB
mutant, are induced to mature into erythrocytes. One of
the first indications of this process is the induction
of haemoglobin synthesis, which can be detected by a
sensitive test (acidic benzidine staining, Orkin et al,
1975, Graf et al, 1978) at the level of the single
cells. Thus, a specific increase in the number of
benzidine—positive cells might be expected, as a
phenotypical effect of a ribozyme directed against erbB
in this test system.
The test series on which this Example is based was
carried out as follows: the various DNA preparations
(see above and Table D), dissolved in 30 pl of TE
buffer, were mixed with 10 pg of native transferrin~iron
complex or transferrin~polylysine conjugate (dissolved
in 50 pl of twice distilled water) and then incubated
for 30 minutes at 37°C.
In the case of the vector DNA (10 pg),
correspondingly more (100 pg) of the transferrin
preparations was used. The DNA transferrin—DNA mixtures
were added to 1 ml of transferrin—free differentiating
medium (Zenke et al., 1988). The test cells (per batch
3x106) were incubated before the test for 60 minutes in
transferrin-free differentiating medium at 42°C (to
intensify the uptake of transferrin) and added to the
DNA—transferrin—containing mixtures. After 6 hours, 18
hours and 68 hours (see below for treatment of cells),
samples were taken as described, separated into
supernatant and cell sediment, taken up in PK/SDS buffer
and the DNA was analysed.
Fig. 12 shows that, analogously to Example 8, in
the cell sample treated with transferrin—polylysine,
about 5-10 times more DNA was absorbed by the cells than
in the control samples with native transferrin.
Trace m: molecular weight marker: pBR322 DNA, cleaved
with HpaII and radioactively labelled using the klenow
of DNA polymerase with alpha~”P—CTP (Maniatis)
2000 cpm ES13 fragment
fragment
Trace 1:
Trace 2: material from cells treated with transferrin
and E813
Trace 3: material from cells treated with transferrin-
polylysine and ES13
After the end of incubation (6 hours) the cells
were centrifuged off and incubated in transferrin-
containing differentiating medium with erythropoietin
and insulin (Kowenz et al, 1986, Zenke et al 1988, 2 ml
per batch and at 37°C, i.e. in the presence of an active
v-erbB protein) for a further 72 hours.
The following results were obtained:
. As in Example 8, an increased uptake of DNA could
be observed in the size of the erbB cut DNAS in the
cell samples treated with transferrin—poly1ysine
(about a 5—fo1d increase).
. Table D shows that in every case where erbB cut
ribozyme tDNA was introduced into erbB transformed
erythroblasts with the aid of polylysine-
transferrin constructs, the percentage of
benzidine—positive cells was significantly
increased (approximately doubled) (the standard
used was the samples treated with vector DNA in
which the use of polylysine~transferrin conjugates,
as expected, did not lead to any increase in the
number of benzidine-positive cells).
Example 1
Efficient binding and internalisation of
transferrin—poly1ysine/DNA complexes in haematopoietic
chicken cells
The binding of TfpL and TfpL—DNA to cell surface
receptors was measured with tritium—label1ed substances
using the method described by Stein et a1., 1984. 3H-
labelled TfpL was prepared by conjugation of labelled
polylysine with transferrin using the method described
in Example 1. The labelling of polylysine 90 was
carried out by treating with formaldehyde and 3H—labelled
sodium borohydride (Ascoli and Puet, 1974). The results
13. Labelled TfpL 90
(squares) or labelled TfpL 90 complexed with pB—SK- DNA
of these tests are shown in Fig.
(Promega Biotech, prepared by Triton—X lysis, CSCl/EtBr
equilibrium density gradient centrifugation,
decolorisation with 1-butanol and dialysis against 10 mM
Tris/HCl pH 7.5, 1 mM EDTA) (triangles) were
investigated for their specific binding to the
transferrin receptor of HD3 cells. For this purpose the
conjugates or complexes (0.1 — 100 nM) were added to HD3
cells (1 X 106/ml in MEM (Eagle's Minimum Medium) + 1%
BSA) and incubated for 3 hours. Fig. 13 shows that both
the conjugates and also the complexes bind to HD3 cells
in such a way that saturation occurs. The apparent
binding constants calculated from these data amounted to
22 nM for TfpL and 43 nM for TfpL-DNA complexes.
Although somewhat higher, these values correspond
relatively well to those obtained for native
transferrin, which were found to be 15 nM (Killisch).
In order to monitor the uptake of TfpL—DNA
complexes into intracellular vesicles, first of all HD3
cells were incubated at 37°C for 18 hours with
transferrin—free differentiating medium. After the
addition of FITC transferrin or TfpL conjugates
(labelled with FITC at the polylysine group, and
complexed with DNA in some experiments), the cells were
incubated for a further 18 hours. The cells were
cytocentrifuged, fixed with a mixture of 3.7%
formaldehyde and 0.02% glutaraldehyde, washed with PBS,
embedded in Mowiol 4.88 and examined under a Zeiss
Axiophot Fluorescence Microscope. The control used
consisted of FITC-labelled goat anti—mouse antibodies
(0.1 mg/ml)
determination of FITC—Tf, FITC—TfpL and FITC—TfpL/DNA,
(see Example 5). For quantitative
the cells were incubated for 6 hours with the
preparation in question (Tf: 40 ug/ml; TfpL270:
pg/ml; TfpL270 plus pB-SK—DNA (Promega Biotech,
prepared by Triton-X lysis, CSCl/EtBr equilibrium
density gradient centrifugation, decolorising with l-
butanol and dialysis against 100 mM Tris/HCl pH 7.5,
1 mM EDTA): 50 pg/ml or 16 pg/ml; binding buffer),
washed 3 times in cold PBS/BSA and subjected to
quantitative FACS analysis in a Becton—Dickinson (BD)
FACSAN.
Fig. 14 shows that both with TfpL and with Tfp
LDNA, all the cells have a relative fluorescence
increased more than 10 times, indicating that the
conjugates or complexes have been taken up by more than
% of the cells (Tf:.....; TfpL:. .; TfpL/DNA: ;
binding buffer:-———).
Example 12
Expression of DNA absorbed into the cell by means
of TfpL
After it had been established in the preceding
Examples that the gene transfer with TfpL is not harmful
to cell growth, the activity of TfpL—DNA complexes which
were used themselves for a longer period of time was
tested (the DNA used was plasmid DNA containing the
luciferase gene, as described in Example 9). In this
test, the same concentration of HD3 cells was incubated
for 1 to 4 days with or without daily supplementing with
TfpL—DNA complexes.
At various intervals of time, aliquots were
investigated for lucerifase enzyme activity, as
described in Example 9. ln the cultures with repeated
addition of the complexes, a relatively high level of
luciferase gene expression was measured (100,000 to
200,000 light units per 107 cells), which remain
substantially constant throughout the entire observation
period. During this period, no cytotoxic effects were
observed. If cells were charged with the complexes only
once, the luciferase activity decreased between the 2nd
and 4th days by a factor of 10 to 20. These results
show that in spite of the obviously transient expression
of the luciferase gene, introduced into the cell with
the aid of the conjugates according to the invention, a
constantly high expression of the introduced genes can
be maintained by repeated addition.
Example 1;
In order to establish how large a proportion of
cells actually express plasmid DNA introduced by
transferrin infection, HD3 cells were incubated with
TfpL/DNA complexes as described in the preceding
Examples.
DNA.
pRSV—fiGal plasmid DNA (__u) was used as the
The expression of this reporter gene was then
investigated in individual cells by FACS analysis (Nolan
et al., 1986). TfpL—pB—SK-DNA (...) was used as the
control. The fluorescence BGa1 substrate FDG
(fluorescene—Di—fi~d—galactopyranoside) was introduced by
osmotic shock and the distribution of cells containing
fluorescene which was released from FDG by the BGal
enzyme activity was investigated. Uniform distribution
of fluorescene—containing cells leads to the conclusion
that a large proportion of cells express the fiGal
reporter gene.
Fig. 15.
The results of these tests are shown in
wucmomwuo:Hw mHoHmm> mnu mo %uHmCmuCH w>HuwHwH map wumUHUcH +++ Ucm ++
Emu ooo.mmH +++w omA +++w ow .00 ohm AmwB H1 m¢H HE N m
Emu ooo.mmH +++w omA +++w om .00 mhm dame H1 m¢H HE m n
Emu ooo.HmH +++w omA +++w om .m0 vum HQMB H1 mvH HE N m
Emu ooo.mmH +++w omA +++w omn mum QQMH H1 mvH HE N m
Emu ooo.HoH +++w OmA +++m omA mum qmwa H: mva He m «
EQU ooo.nmH ++w omA ++w omA Hum AQMB H1 mva HE N m
Emu ooo.omH w Hv w HV omm H1 mva HE N N
Emu ooo.ovH N Hv W Hv coHuHUUm u5o£uH3 HE m H
E mv E mv S vm
ACOHUGHOQHOOCHIM UH mmv wocmomwuo5Hm wcHm%H%H0m
%PHHHQMH> wHOHmm> IQHHHwmmCwHB EUHUWS nuumm
mHmflHQOHSH%H@ oucH
< GHQMB
cHuMwwwcmuu:mcHm>H%Hom we mcHuuommcmHB
H1 oma \ONm “Hi oma CH 0: OON COHHOGHMIQQWH «H1 ma CH ®1 ooN ‘CHHHOWWCGHUIGM "Q
U®CflEH®P®U HOE um
N mouom mm.H vH.H v.« wm.m mum qmwe HE N m
.n.c nw.N a«.H oN.« mm.m mum game HE N m
.n.: mm.N nm.H mm.¢ mv.m «um qmwe HE N n
womA vm.N mm.a vm.« Nn.m mum QQMH HE N m
w.Q.c am.N mH.a vN.v mm.m Nam QQMB afi N m
N owA mo.N mm.H ««.« on.m Hum QQMH HE N «
N av mH.o om.o N¢.N om.N ONE a5 N m
W av mN.o mm.o ®m.N N©.N l HE N N
w OwA vh.N wm.H mm.w wN.m cfluumumcwuuumm HE N H
3 Nu Q mw Q ¢N Q mv Q «N
mmumooasoflumu N Nmq m AHE\moa xv
%PHH5#ME
MO mmhmmo cflnoamofiwmm maamo mo oz ncofluflvva Efiflfimz OZ
WUWflHQOHCU%H® W0 COHPMMSUME U®U5UCHlOHUH>
COHUfiH5EHUW QQU CH CHHHQMMCMHP HMEHOC QUMHQQH %HH®COHUUC5W
m GHQME
mm man we
C00 cflnuwwmcwuulmcflmmamaom
v N» m mmo.H on.m I uoumIwH I
n mm oa mao.H «o.m I omamme I
o m» m mmm.a mm.m I I I
am av mm mmm.o a.m I I I m
.c.c mom.m ov.« o:q>mmm omamwe I
9 .c.c mmw.m ww.m o:q>mmm I I
3
.:.c mN.o «m.H osq>mmm I I N
« om aa mom.a om.m I onmamme I
w «m m moa.H >m.m I omamwa I
a mu m >mm.a mn.m I I I
«v av mm mmm.o om.m I I I H
Ham m+mq maawu Ammvmv Aasxmoaxv mumwsncou
w w .UCHmmU am Mwnfisc aamu <20 CHHHOWMEMHH cfihumwmcmufi umme
Hwumfimuwm COHUflH#C®H®MwHQ
U QHQMB
COHUHUUQ IEDHUmE
MUCQEQMSMMQE ufimwammmuca mo .02 "Q
QOwum.a>®U UHMUCGUW I HO + mwsams. \UC®E®<.H5m.©wE EOMG .HOw USO UQUCSOU ®.H®3 WHHQU OON Camp QHOE um
Amv mu+mm av on oa mum amwe mi m.o+m.o mm + ma usounuw m
Amy m:+am av an oa we wz m.o+m.o .o.m mm + ma uzounnw A
®E%NOQHH
Amv m:+mm av mu ooa mum amue ma oa psonuaz nouuw> m
mE%NODfiH
Amy m«+mm av mu ooa we mu oa ooaxm usonuaz uouom> m
“NV au+m« av on oa mum amme mm usosnum v
Amv mu+mm av vi oa we on a moaxm mm usuunuw m
Amv ¢u+nm av mi oa mum amwe ma usonnuw m
namv wma+ma av mi oa we on a moaxm ma usounum a
S No a va ucSoE< mama uc50E¢ 32 mmme
Amcacamum QCHUHNCGQ
oaumow map mo w>auamom wv
UCODCOO CHQOHUOEQMHM Cwuuwwmcmue ANZQ OZ
<20 mE%NOQHH I mQamu>
Uwnhomnm m>m£ EUHQ3 mummanouaulmum Uwfihowmcmuu I mQHwI> MO AU.C®u.CO0 CHQOHUOEGMQV COHHMHSHME
Q ®HQmB
Bibliography
Ascoli, M and Puett, D.
371, 203-210.
Beug, H., et al., (1982a), J. Cell Physiol. Suppl. 1
195-207.
Beug, H., et al., (1982b), Cell 28, 907-919.
Beug, H., et al. (1984), Cell 36, 963—972.
Cormier et al., (1988), Nucleic Acids Res. 16, 4583.
Deakin, H., et al., (1963), Biochem.J. 89, 296.
Graf et al., (1978), Nature 275, 496~501.
Huebers et al., (1987), Physio1.Rev. 67, 520-582.
Jung et al., (1981), Biochem.Res.Commun. 101, 599.
Kahazaie, K., et al., (1988), EMBO J., 10, 3061-3071.
Kowenz, E., et al., (1986), Mod.Trends in Human Leukemia
VII, Springer Verlag, pp. 199~209.
Lemaitre et al., (1987), Proc Natl Acad Sci. 84, 648.
Maniatis et al., Molecular Cloning, Cold Spring Harbor
1982
Morvan et al., (1988) Nucleic Acids Res. 16, 833.
Nolan, G P., et al., (1986), Proc.Nat1.Acad.Sci. 85,
2603~2607
(1974), Biochem.Biophys. Acta
Praseuth et al., (1988), Proc.Natl.Acad.Sci. 85, 1349.
Orkin, et al., (1975), Proc.Natl.Acad.Sci. 72, 98—102.
Radke, K., et al., (1982), Cell 31, 643-653.
Schmidt et al., (1986), Cell 46, 41»51.
Smith et al., (1986), Proc.Nat1.Acad.Sci. 83, 2787.
Stavridis, J.C. and Psallidopoulos, M., 1982, Cell. Mol.
Biol. 28(1), 15—18.
Stein et al., (1984), J. Bio1.Chem. 259, 14762~14772.
Stein et al., (1988), Nucleic Acids Res. 16, 3209.
Stirchak et al., (1987), J Org.Chem. 52, 4203.
Wu, G.Y., et al., (1988), J.BiOl.Chem. 263, l462l—14624.
Zamecnik et a1. (1986), Proc.Nat1.Acad.Sci. 83, 4143.
Zenke, M., et al., (1988), Cell 52, 107-119.
Claims (17)
1. Conjugate consisting of transferrin and a polycation covalently bound thereto, characterised in that the polycation is a synthetic homologous polypeptide or a polyethyleneimine.
2. Conjugate according to claim 1, characterised in that the synthetic homologous polypeptide is a polylysine.
3. Conjugates according to claim 1 or 2, characterised in that the polycation contains about 20 to about 500 positive charges.
4. Transferrin—polycation/nucleic acid complex which is absorbed into the human or animal cell by transferrin receptor—mediated endocytosis, containing a conjugate according to one of claims 1 to 3.
5. Complex according to claim 4, characterised in that it contains as nucleic acid a nucleic acid capable of specifically inhibiting genes or RNA function.
6. Complex according to claim 5, characterised in that it contains a nucleic acid capable of inhibiting viral nucleic acid.
7. Complex according to claim 5, characterised in that it contains a nucleic acid capable of inhibiting oncogenes or other key genes which control cell growth and/or differentiation.
8. Complex according to one of claims 5 to 7, characterised in that it contains as nucleic acid a ribozyme, optionally together with a carrier RNA, or the gene coding for it.
9. Complex according to claim 8, characterised in that it contains as nucleic acid a genetic unit consisting of a tRNA gene as carrier gene and a ribozyme gene arranged inside this gene.
10. Complex according to one of claims 5 to 7, characterised in that it contains as nucleic acid an antisense-oligonucleotide, optionally together with a carrier nucleic acid, or in the case of an RNA oligonucleotide, the gene coding therefor.
11. Complex according to claim 4, characterised in that it contains a nucleic acid coding for a protein.
12. Process for introducing nucleic acid(s) into human or animal cells in vitro by transferrin receptormediated endocytosis, wherein a complex which is preferably soluble under physiological conditions is formed from transferrin-polyeation conjugate and nucleic acid or acids and the cells are brought into contact with this complex, characterised in that a conjugate as defined in claim 1 is used.
13. Pharmaceutical preparation containing one or more of the complexes defined in claims 4 to 11.
14. A Conjugate according to any one of claims 1 to 3, substantially as hereinbefore described.
15. A transferrin—polycation/nucleic acid complex according to any one of claims 4 to 11, substantially as hereinbefore described.
16. A process according to claim 12, substantially as hereinbefore described.
17. A pharmaceutical preparation according to claim 13, substantially as hereinbefore described. Tomkins & Co.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE93290A IE900932L (en) | 1990-03-15 | 1990-03-15 | Protein-polycation-conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATAUSTRIA16/03/1989A610/89 | |||
IE93290A IE900932L (en) | 1990-03-15 | 1990-03-15 | Protein-polycation-conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
IE83273B1 true IE83273B1 (en) | |
IE900932L IE900932L (en) | 1990-09-16 |
Family
ID=11019937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE93290A IE900932L (en) | 1990-03-15 | 1990-03-15 | Protein-polycation-conjugates |
Country Status (1)
Country | Link |
---|---|
IE (1) | IE900932L (en) |
-
1990
- 1990-03-15 IE IE93290A patent/IE900932L/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5354844A (en) | Protein-polycation conjugates | |
Zenke et al. | Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. | |
CA2012312C (en) | Genetic units for inhibiting the function of rna | |
Huckett et al. | Evidence for targeted gene transfer by receptor-mediated endocytosis: Stable expression following insulin-directed entry of neo into HepG2 cells | |
Pichon et al. | Histidine-rich peptides and polymers for nucleic acids delivery | |
DE69725878T2 (en) | COMPOSITIONS FOR POLYNUCLEOTIDE DELIVERY | |
US6177554B1 (en) | Nucleic acid transporter systems | |
CA2192687C (en) | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells | |
US6372720B1 (en) | Liposome fusion and delivery vehicle | |
US6740524B1 (en) | Nucleic acid transfer phage | |
CA2143308A1 (en) | Translocation signal facilitated nuclear delivery of macromolecules | |
Frese Jr et al. | Targeting of genes to the liver with glycoprotein carriers | |
US5843770A (en) | Antisense constructs directed against viral post-transcriptional regulatory sequences | |
US5922859A (en) | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells | |
JP3556214B2 (en) | New protein-polycation conjugate | |
Nakanishi et al. | Gene transfer vectors based on Sendai virus | |
IE83273B1 (en) | New protein-polycation-conjugates | |
JP3808938B2 (en) | Nucleic acid carrier | |
US6830923B1 (en) | Genetics units for inhibiting the function of RNA | |
WO1999015687A1 (en) | Multicomponent polynucleotide complex for high efficiency cell transfection |